Omixon and AGBL Partner on an Extensive Middle East and North-Africa Distribution Deal
BUDAPEST, Hungary, and CAMBRIDGE, Mass., and DUBAI, U.A.E., Nov. 29, 2018
BUDAPEST, Hungary, and CAMBRIDGE, Mass., and DUBAI, U.A.E., Nov. 29, 2018 /PRNewswire-PRWeb/ -- Global molecular diagnostics company Omixon, headquartered in Budapest with US offices in Cambridge, MA and Alliance Global FZ-LLC, headquartered in Dubai, UAE announce today the execution of an exclusive distribution agreement to cover markets in the Middle East, Africa and Central Asia. The partnership builds on Omixon's existing customer base in some of the covered markets including Saudi Arabia and Kuwait. AGBL will further extend Omixon's offering to U.A.E, Saudi Arabia, Oman, Turkey, Iran, Uzbekistan, Kyrgyzstan, Tunis, Morocco, Algeria, Egypt, Qatar, Lebanon, Iraq, Syria, Jordan and Armenia through its rich customer database.
AGBL's science team will offer technical counseling to customers across the covered markets, while its sales and technical support teams will support customer's commercial and technical needs to insure that their research and diagnostics needs are met. Omixon's product offering will allow researchers in the covered geography to explore new frontiers in HLA and ABO typing, though high-performance, high-throughput and high-resolution assays and analysis software.
"We are excited to working alongside AGBL. Their commitment to excellence, knowledge of the local HLA typing markets, deep regional coverage, extensive technical support and implementing NGS for HLA in clinical labs will certainly strengthen our global presence and increase the level of expertise in NGS," commented Marcello Scala, VP Sales, EMEA & Asia, Omixon.
"Our partnership with AGBL not only increases the access to Omixon's products through new channels, but simultaneously extends the commitment we made to our HLA community to bring the latest technology and complete solutions, something Omixon have continually strived to do," said Nora Nagy, Head of Market Development and Marketing.
"The partnership with Omixon is another important addition to our offerings to genomics customers in emerging markets, we believe that their innovative products and software will help many of our existing and potential customers and we are very excited about the future of this partnership," said Dr. Nassim-Marie Hambouz, Director of Commerical Operations at the AGBL Group
Omixon is a global molecular diagnostics company, headquartered in Budapest, Hungary, with US offices in Cambridge, MA that commercializes disruptive technologies for clinical and research laboratories. Omixon's flagship product, Holotype HLA, is the world's leading NGS-based HLA genotyping product that delivers the most accurate high-resolution HLA genotyping available, and is used in more than 45 hospitals worldwide. Omixon's research software, HLA Explore analyzes data from any sequencing technology and determines HLA genotypes from Whole Exome/Genome Sequencing experiments. Omixon maintains an active grant-funded research program with a product pipeline focused on pre- and post-transplantation, and HLA genotyping applications beyond transplantation. For more information, visit http://www.omixon.com
About Alliance Global Group (AGBL) The AGBL Group of companies is the largest biomedical gateway to the emerging markets of the Middle East, Africa and Asia. The group is dedicated to bringing innovative technologies and products to researchers, clinicians, and diagnostic users in the emerging healthcare markets within the MEAA region. The group's stated mission is to improve the lives of the region's inhabitants through novel biomedical technologies and products. For more information, please visit: http://www.agbl.net
All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to future uses, quality or performance of, or benefits of using, products or technologies, the expected benefits of the agreement between AGBL and 4Bases and other future events. AGBL undertakes no obligation to revise or update information in this press release to reflect events or circumstances in the future, even if new information becomes available.